Actively Recruiting
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Led by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace · Updated on 2026-02-04
30
Participants Needed
2
Research Sites
98 weeks
Total Duration
On this page
Sponsors
G
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Lead Sponsor
I
Institut de Recherche en Hématologie et Transplantation (IRHT)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
CONDITIONS
Official Title
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 60 years or older
- For control group: scheduled for cardiac surgery involving sternotomy
- Normal blood count within two months before sampling (control group)
- Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled for azacitidine-based treatment (AML group)
- Affiliated with or beneficiary of a social security system
- Written informed consent to participate in the study
You will not qualify if you...
- Patients unsuitable for sampling by the surgeon (control group)
- Patients under legal protection measures
- Patients under judicial supervision or deprived of liberty by judicial or administrative decision
- Presence of active infection markers (hepatitis B, hepatitis C, or HIV)
- Diagnosis of a hematologic disease other than AML (AML group)
- Clinical signs suggesting active central nervous system leukemia or isolated extramedullary leukemia (AML group)
- Previous AML treatment other than hydroxyurea (AML group)
- Severe comorbidities interfering with the study as assessed by the principal investigator (AML group)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Groupe Hospitalier de la Région de Mulhouse et Sud Alsace
Mulhouse, Alsace, France, 68100
Actively Recruiting
2
GHRMSA
Mulhouse, France, 68100
Actively Recruiting
Research Team
B
Bernard DRENOU, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here